Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glucose transporter proteins in parasitic protozoa and some helminths are integral membrane proteins belonging to the major facilitator superfamily (MFS), facilitating the import of glucose (and often other hexoses) across the parasite plasma membrane. Parasites such as Plasmodium, Leishmania, and Trypanosoma rely heavily on glucose for energy due to limited metabolic pathways, making these transporters essential for growth, replication, and virulence. Multiple transporter isoforms may be present, each with distinct expression patterns and subcellular localizations; for example, Leishmania mexicana expresses LmGT1 in flagella, and LmGT2/3 in the cell body. Inhibition of these transporters using small molecules can effectively starve parasites of glucose, offering a promising strategy for novel antiparasitic drugs, but selectivity and safety remain key challenges due to the similarity to human transporters.
Inhibition of glucose uptake—drugs block glucose binding or transport, starving the parasite of energy and leading to growth inhibition or death
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parasitic glucose transporter (PfHT, LmGT1–3, CsGLUT).